Grove Bank & Trust Decreases Holdings in Eli Lilly and Company $LLY

Grove Bank & Trust decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 16.6% in the fourth quarter, Holdings Channel reports. The fund owned 7,908 shares of the company’s stock after selling 1,574 shares during the quarter. Grove Bank & Trust’s holdings in Eli Lilly and Company were worth $8,499,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Laurel Wealth Advisors LLC lifted its stake in shares of Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares during the last quarter. Norges Bank purchased a new position in shares of Eli Lilly and Company in the 2nd quarter worth approximately $8,827,714,000. Capital Research Global Investors increased its position in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares during the last quarter. Amundi increased its position in shares of Eli Lilly and Company by 27.1% during the 3rd quarter. Amundi now owns 4,525,902 shares of the company’s stock valued at $3,823,977,000 after purchasing an additional 964,675 shares during the last quarter. Finally, Victory Capital Management Inc. raised its holdings in Eli Lilly and Company by 47.6% during the 3rd quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company’s stock valued at $1,761,772,000 after buying an additional 744,868 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

LLY has been the subject of a number of analyst reports. HSBC downgraded Eli Lilly and Company from a “hold” rating to a “reduce” rating and lowered their price target for the stock from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Morgan Stanley reiterated an “overweight” rating and set a $1,313.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, March 5th. Jefferies Financial Group set a $1,300.00 target price on shares of Eli Lilly and Company and gave the company a “buy” rating in a research note on Friday, March 13th. Scotiabank reaffirmed an “outperform” rating and set a $1,300.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Finally, CICC Research upped their price target on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a report on Wednesday, February 11th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,221.44.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock opened at $910.59 on Tuesday. The stock’s fifty day moving average is $1,019.76 and its two-hundred day moving average is $960.48. The company has a market capitalization of $860.34 billion, a PE ratio of 39.68, a price-to-earnings-growth ratio of 1.05 and a beta of 0.40. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion during the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period last year, the company earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Expanded patient access/pricing for Zepbound — Lilly will offer a self-pay option starting at $299/month for a low dose and expand distribution via LillyDirect and major pharmacies, which could widen the addressable market and reduce payer friction. Eli Lilly Expands Zepbound Access
• Positive Sentiment: Analysts trimming and raising targets after strong quarterly results — multiple outlets note analyst upgrades and upside estimates following Lilly’s February quarter beats and raised FY‑2026 EPS guidance, supporting investor confidence. Analyst Upside Coverage
• Positive Sentiment: Positive Phase‑3 ADorable‑1 topline results announced — a favorable readout (topline) from a Phase‑3 trial bolsters pipeline optionality beyond weight‑loss products, which could add long‑term value if confirmed in full data and regulatory filings. ADorable-1 Topline Results
• Positive Sentiment: Manufacturing / international expansion discussions — Lilly leadership is engaged with Indian officials on “Make in India” steps, signaling potential capacity/market expansion outside the U.S. that could support production and revenue growth. Make in India Meeting
• Neutral Sentiment: Executives ramping China engagement — Lilly joined U.S. peers at the China Development Forum; management signals cautious investment in China, which is an opportunity for growth but carries geopolitical and execution risks. China Development Forum Coverage
• Neutral Sentiment: Local permitting / community concerns around new plant — planners in Lehigh Valley will discuss traffic and other issues tied to a proposed Lilly site; routine for expansion but could delay timelines. Lehigh Valley Plant Discussion
• Negative Sentiment: Supreme Court revives Actos litigation — the court’s action reopens potential legal exposure tied to Actos, creating an earnings/contingent‑liability risk that investors will watch for scope and financial impact. Actos Litigation Revival

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.